USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 27, 2024 /PRNewswire/ -- USA News Group News Commentary – According to the American Cancer Society, 2024 will be the first year the USA expects to have more than 2 million new cancer cases. In order to respond to the rising rates of cancer, the National Cancer Institute is making calls for change in how cancer clinical research is performed "Because our patients can't wait." According to Spherical Insights, the Glo ...

公司管理层变动 - 公司宣布现任总裁兼首席执行官Matt Coffey博士因健康原因将立即开始医疗休假，期间由董事会主席Wayne Pisano担任临时CEO [1] 公司战略与产品进展 - 公司对现有管理团队的能力充满信心，将继续推进pelareorep的注册支持性临床计划，这是一种在乳腺癌和胰腺癌中具有差异化潜力和可能领先地位的免疫治疗药物 [2] - 公司正在推进pelareorep在转移性乳腺癌和胰腺癌中的注册研究，这两种适应症均已获得FDA的快速通道指定 [5] 产品介绍 - Oncolytics Biotech Inc.是一家临床阶段的生物技术公司，专注于开发pelareorep，这是一种通过静脉注射的免疫治疗药物，已在转移性乳腺癌和胰腺癌的多个临床研究中显示出有希望的结果 [4] - pelareorep通过诱导抗肿瘤免疫反应并促进肿瘤炎症表型，使“冷”肿瘤变为“热”肿瘤，从而使由pelareorep诱导的抗肿瘤免疫细胞攻击癌症 [4] 管理层背景 - Wayne Pisano自2013年起担任董事会主席，拥有超过30年的制药行业经验和超过12年的生物技术行业经验，曾担任VaxInnate的总裁，并在多家生物技术公司担任董事会成员，包括Provention Bio和Altimmune Inc. [2] - Pisano曾担任Sanofi Pasteur的总裁兼CEO，这是全球最大的疫苗公司之一，他推动了Sanofi Pasteur在全球流感市场的领导地位，占据了全球销售额的50%，并通过收购Acambis PLC和Shantha Biotechnics加强了公司的疫苗管线 [3]

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 20, 2024 /PRNewswire/ -- USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer cases in younger age groups than before. While researchers continue to search for a reason why this is happening, some are pointing towards increased rates of obesity, among other potential reasons. With the Global Oncology Drugs Market set to g ...

Demonstrating pelareorep's synergy with modified FOLFIRINOX +/- atezolizumab in pancreatic cancer could expand the number of patients it may benefit Funding for the study comes from the US$5 million Therapeutic Accelerator Award from PanCAN SAN DIEGO, and CALGARY, AB, June 20, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, announced the dosing of the first patient in the new GOBLET study cohort evalua ...

USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 19, 2024 /PRNewswire/ -- USA News Group – This year's 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without increasing hope for cancer patients around the world. This year's ASCO 2024 theme was 'The Art and Science of Cancer Care: From comfort to cure,' with attendees hearing presentations from experts and receiving a wide range of important clinical results for t ...

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2024 /PRNewswire/ -- After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may be experiencing larger per-capita increases in the incidence of leading cancers, including the very deadly pancreatic cancer, compared to previous generations. The startling revelations come from a study conducted by experts at the National Cancer ...

A downtrend has been apparent in Oncolytics Biotech Inc. (ONCY) lately. While the stock has lost 9.3% over the past four weeks, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support. While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about ...

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 3, 2024 /PRNewswire/ -- USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by focusing on earlier detection. According to Johns Hopkins Medicine, up to 80% of patients are diagnosed at advanced stages, which are significantly harder to treat. A new study published in the journal Cell Genomics demonstrates that researchers have ...

USA News Group Commentary VANCOUVER, BC, May 28, 2024 /PRNewswire/ -- USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale Medicine. As well, there are now alarming reports around the world of rising diagnoses of HIV, which is being linked to higher anal cancer mortality for women. Worldwide, improved access to testing led to a 4.2% increase in HIV diagnoses in the EU and a whopping 120% increase in Montreal, Canad ...

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 24, 2024 /PRNewswire/ -- USA News Group News Commentary – As the 2024 American Society of Clinical Oncology (ASCO) annual meeting approaches, excitement builds over the latest in cancer treatment advancements, particularly in Antibody-Drug Conjugates (ADCs). From May 31 to June 4, industry leaders will unveil new data on late-stage and approved therapies. Recent FDA approvals are also enriching the treatment landsc ...